PODD Insulet Corporation
Company Analysis
Latest News
🟢 Insulet is trading 4.3% up today amid healthcare-sector strength
Insulet is trading 4.3% up at $137.62 after a sharp multi-session decline, with the move appearing primarily tied to healthcare-sector strength. - XLV is up...
Insulet Announces Departure of Two Board Members, Citing Health and Political Candidacy
Insulet Corporation announced the resignation of two members from its Board of Directors, Timothy J. Scannell and Michael R. Minogue. Mr. Scannell's departure...
Insulet Offered Record $40M State Incentive, Retaining Acton Medical Manufacturing
Massachusetts officials offered Insulet Corp. (PODD) a record $40 million incentive package. The deal aims to keep the Omnipod insulin system manufacturer's...
🔴 Insulet falls 4.0% — Healthcare Stocks Fall as Insurance Crisis Deepens
With Healthcare (XLV) down 2.2%, this looks like a sector-led move rather than a company-specific surprise. The healthcare sector is experiencing a...
🟢 Insulet is trading 6.31% up in after-hours trading with limited support from broader market gains
Insulet is trading 6.31% up at $157.49 after closing at $148.14 on September 2, 2026, with limited support from broader market gains. - No September 2...
Insulet faces class-action deadline, following alleged Omnipod manufacturing defects
Robbins Geller Rudman & Dowd LLP and Faruqi & Faruqi, LLP reminded investors of an August 31, 2026, deadline to seek lead plaintiff status in a class-action...
🟢 Insulet is trading 11.08% up in after-hours trading; immediate trigger remains unclear
Insulet is trading 11.08% up at $164.43 after closing at $148.03 on August 18, 2026; the immediate after-hours trigger remains unclear. - Available August 18...
🟢 Insulet is trading 4.7% up today as healthcare gains 1.59%
Insulet is trading 4.7% up at $146.34, outperforming a broadly weaker market as healthcare gains 1.59% during the regular session. - No new positive...
🟢 Insulet is trading 15.13% up in after-hours trading
Insulet is trading 15.13% up at $167.01 after closing at $145.06 on August 12, 2026; no clear company-specific catalyst explaining the after-hours surge was...
🟢 Insulet is trading 9.51% up in after-hours trading
Insulet is trading 9.51% up at $158.85 in after-hours trading, but the catalyst remains unclear. - Shares closed at $145.06 on August 12, 2026. - No new...
Insulet Corporation faces securities class action lawsuit
Multiple law firms filed a class action lawsuit against Insulet Corporation. The suit alleges violations of federal securities laws. It claims Insulet made...
Insulet Beats on Every Q2 Metric Then Cuts the Outlook — Can the Type 2 Diabetes Bet Still Justify the Stock Price?
Shares of Insulet Corporation cratered 10.1% to $149.98 after the insulin-pump maker delivered a paradox: a strong quarter followed by a weaker road ahead....
🟢 Insulet is trading 4% up today as healthcare stocks gain
Insulet is trading 4% up at $138.59, with healthcare-sector strength providing the immediate backdrop. - It rebounded from the 20.12% decline on August 5. -...
🔴 Insulet is trading 23% down today as 2026 sales guidance cut offsets Q2 beat
Insulet is trading 23% down at $131.65 after its second-quarter earnings release showed strong revenue and EPS beats but a cut to full-year 2026 sales...
🔴 Insulet is trading 10.1% down today on lowered FY26 sales outlook and Omnipod guidance
Insulet is trading 10.1% down at $149.98 after the company lowered its long-term sales outlook despite beating Q2 earnings expectations. • The company cut its...
Insulet's second quarter revenue grew 23.5% to beat estimates, but the company lowered its full-year 2026 sales forecast.
Insulet reported second quarter revenue of $801.7 million, up 23.5% year-over-year, and adjusted EPS of $1.66. These results surpassed analyst expectations for...
Insulet Corporation Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect Insulet to report Q2 2026 revenue of $787.4 million and earnings of $1.44 per share, with the stock currently trading at $165.35 against an...
🔴 Insulet is trading 4.6% down today as managed care concerns weigh on healthcare
Insulet is trading at $161.99 (4.6% down) as managed care concerns drag the broader healthcare sector lower despite positive performance in the wider...
Insulet Tumbles as UBS Slashes Omnipod Maker’s Price Target to $174
UBS downgraded Insulet Corp. (PODD) from Buy to Neutral on July 28, 2026. The investment bank slashed its price target for the medical device company to...
🟢 Insulet is trading 4.4% up today amid a broader healthcare sector bid
Insulet is trading at $172.25 (+4.40%) amid a broader healthcare sector bid and a rotation into defensive names, despite a lack of company-specific news. •...